VIRBAC CORPORATION APPOINTS STEVEN BUCHHOLZ VICE PRESIDENT, QUALITY & COMPLIANCE

Fort Worth, Texas (July 13, 2015) – Virbac Corporation today announced that Dr. Steven Buchholz has been appointed to the position of Vice President, Quality Compliance.

In the role of Vice President, Quality Compliance, Steve will play a pivotal leadership role in ensuring the quality of our products by: developing, executing, and firmly establishing quality systems; developing and implementing strategies for regulatory compliance; designing product quality and process requirements in accordance with established company policy and global regulatory requirements.

Steve has a Ph.D. in microbiology from Rutgers University and a B.S. in biological sciences from the University of Connecticut. Most recently, he was Principal Consultant for Parexel International, and served as lead on its current project with Virbac. Prior to his role at Parexel, Steve ran his own consulting practice, drawing on his years of experience through progressive roles in production, research, quality and compliance at Gallus Biopharmaceuticals, where he was Sr. Director of Quality Regulatory; Pfizer, where he served as an Associate Research Fellow; Idec Pharmaceuticals, as Sr. Director Production Logistics, and, Hoffman-LaRoche, where he was Technical Support Fermentation Manager.

Paul R. Hays, President CEO of Virbac U.S., said "We are very pleased that Steve will be leading our Quality Compliance activities. He will be an invaluable asset to all of us as we make decisions to ensure our compliance while striving for our business' success."

One of the world's largest laboratories dedicated exclusively to animal health, Virbac develops, manufactures, and distributes a wide range of products and services intended for the prevention and treatment of common pathologies in companion animals. Virbac Corporation, located in Fort Worth, Texas, is a leading companion animal health company offering products in the heartworm, tick and flea, dermatology, antibiotic, endocrinology, senior care, behavior, critical care nutrition, and oral hygiene markets.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…